Examkin

Question

Difficulty: EasyPharmacologic Interventions

A 28-year-old primigravida at 14 weeks gestation is evaluated in the emergency department for a newly developed, painful swelling in her left lower extremity that began two days ago. She has no significant past medical history and takes only a daily prenatal vitamin. Her vital signs are: blood pressure 112/70 mmHg112/70\text{ mmHg}, heart rate 88/min88/\text{min}, respiratory rate 16/min16/\text{min}, and pulse oximetry 99%99\% on room air. Physical examination reveals pitting edema, erythema, and tenderness localized to the left calf and thigh. A complete blood count and comprehensive metabolic panel are within normal limits. Compression ultrasonography of the left lower extremity reveals a non-compressible left femoral vein, confirming the presence of an acute deep vein thrombosis (DVT). Which of the following is the most appropriate pharmacologic intervention for this patient?

  1. Subcutaneous enoxaparinAnswer
  2. B
    Oral warfarin
  3. C
    Oral rivaroxaban
  4. D
    Oral aspirin
  5. E
    Intravenous argatroban

Answer

Subcutaneous enoxaparin
The correct answer is subcutaneous enoxaparin. Pregnancy induces a prothrombotic state, significantly increasing the risk of venous thromboembolism (VTE). Low-molecular-weight heparins (LMWH), such as enoxaparin, are the standard of care for the acute management of DVT during pregnancy. They do not cross the placenta, are highly effective, and possess a more favorable safety profile (including a lower risk of bleeding, osteoporosis, and heparin-induced thrombocytopenia) compared to unfractionated heparin.

Step-by-Step Solution

1
Evaluate the patient's presentation and current physiologic state.
The patient is a hemodynamically stable pregnant woman (14 weeks gestation) diagnosed with an acute deep vein thrombosis (DVT).
Pregnancy represents a uniquely hypercoagulable state with specific, stringent contraindications for many standard pharmacologic therapies.
2
Identify safe and effective anticoagulant options for use during pregnancy.
Heparin-based products (both unfractionated heparin and low-molecular-weight heparin) are safe choices for anticoagulation in pregnant women.
Their large molecular size prevents them from crossing the placental barrier, thereby eliminating the risk of teratogenicity to the fetus.
3
Select the most appropriate first-line agent based on current clinical guidelines.
Low-molecular-weight heparin (e.g., subcutaneous enoxaparin) is the preferred treatment.
It offers a more predictable pharmacokinetic profile, a lower risk of heparin-induced thrombocytopenia, and does not require routine aPTT monitoring compared to unfractionated heparin.

Key Concept

Management of Venous Thromboembolism in Pregnancy
Estimated Time:1m 0s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic